The BinaxNOW COVID-19 Ag Card Home Test is an immunochromatographic membrane assay that uses highly sensitive antibodies to detect SARS-CoV-2 nucleocapsid protein from nasal swab specimens.
At-Home OTC COVID-19 Diagnostic Tests | FDA
2025年1月17日 · These at-home OTC COVID-19 diagnostic tests are FDA authorized for self-testing at home (or in other locations) without a prescription. Tests are available online or at local stores and you...
BinaxNOW™ COVID-19 Ag test card - Abbott Point of Care
Abbott has designed the BinaxNOW™ COVID-19 Ag Card for decentralized testing, so you can test right at the point of care and get results for your patients quickly and easily. The BinaxNOW COVID-19 Ag Card test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).*
The GenBody COVID-19 Ag is an immunochromatographic rapid diagnostic test (RDT) intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal...
BINAXNOW: TAKING COVID-19 TESTING TO A NEW LEVEL
The BinaxNOW COVID-19 Ag 2 Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swab samples from COVID-19 symptomatic individuals tested twice over three days with at least 36 hours between tests within the first seven days of symptom onset.
Panbio COVID-19 Ag Rapid Test Device | Abbott Point of Care
For patients suspected of current COVID-19 infection. Requires no instrumentation and provides results in 15 minutes, making it a valuable tool for mass testing in decentralized settings.
The BinaxNOW™ COVID-19 Ag Card is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swab samples collected by a healthcare provider from individuals who are suspected of COVID-19 within seven (7) days of
Covid-19 AG BSS - Biosynex
BIOSYNEX COVID-19 Ag BSS test is a rapid in vitro immunochromatographic assay for the qualitative detection of nucleocapsid (N) protein antigen of SARS-CoV-2 in nasopharyngeal or nasal swab specimens. It is designed to assist in the rapid diagnosis of SARS-CoV-2 infections.
Antigen Test Control BinaxNOW™ COVID-19 Ag - McKesson
The BinaxNOW COVID-19 Ag Card is a lateral flow immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from anterior nasal (nares) swab specimens collected from individuals who are suspected of COVID-19 by their healthcare provider within seven days of the onset of symptoms
Upping the ante on COVID-19 antigen testing - Abbott
2020年8月26日 · Cue our sixth COVID-19 test, the BinaxNOW ™ COVID-19 Ag Card rapid antigen test, which has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). This test offers results in 15 minutes and is available as an aid to diagnose the virus that causes COVID-19.